Detection of recombinant human luteinising hormone (rLH) as a doping agent
Detection of recombinant human luteinising hormone as a doping agent in healthy male volunteers aged 18 to 45. An open label, randomised clinical study.
Sydney South Western Area Health Service (SSWAHS)
64 participants
Nov 23, 2004
Interventional
Conditions
Summary
Sports anti-doping study
Eligibility
Inclusion Criteria1
- Healthy males
Exclusion Criteria1
- No recent history of steriod use
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Half of the participants will have a 200mg injection of Nandrolone decanoate, then 3 days later a single dose of rLH 75IU or 225IU or recombinant human chorionic gonadotropin 'rhCG' 250ug or 750ug . Those given 'rhCG' will have another 100mg dose of Nandrolone decanoate the following day. The other half of the participants will be given either a single dose of either rLH 75IU or 225IU or rhCG 250ug or 750ug without the Nandrolone. Blood and urine samples will be obtained at intervals form 0 for up to 8 days.
Locations(1)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12608000181303